73P - Outcome of early-stage lung cancer treated with stereotactic body radiotherapy (SBRT)

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Early Stage
Surgery and/or Radiotherapy of Cancer
Presenter Manal Alameddine
Citation Annals of Oncology (2015) 26 (suppl_1): 18-23. 10.1093/annonc/mdv048
Authors M. Alameddine1, J. Chan2, A. Pope2, A. Haridass2, A. Baker2, S. Meara2, R. Clements2, A. Crabtree2, H. Wong2, C. Eswar2
  • 1Clinical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, CH63 4JY - Wirral/UK
  • 2Clinical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral/UK



Stereotactic body radiation therapy (SBRT) is a technique that utilises precisely targeted radiation to a tumour while minimising radiation to adjacent normal tissue. The targeting allows treatment of small or moderate-sized tumours in either 3, 5 or 8 fractions. SBRT is increasingly being used to treat patients with medically inoperable stage I non-small cell lung cancer and has been reported to be safe and effective. The aim of this study is to review our centre's results with SBRT.


We carried out a retrospective review of 136 patients with early-stage lung cancer who received SBRT. Prior to treatment patients were evaluated with regards to tumour stage and histology, co-morbidities, WHO performance status and lung function test. Following treatment, patients were assessed at 2 and 6 weeks, then at 3 monthly interval in the first year, 6 monthly interval in the second year then yearly up to 5 years. Outcome measures included CTCTAE v4.0 toxicity profile and response to treatment.


There were 69 male and 67 female with a mean age of 73 (range: 43-89 years). Sixty-five percent of patients had moderate to severe co-morbidities, 90% had a performance status of 2 to 3 and 23% preferred SBRT to surgery. Histology was confirmed in 58%. Staging of T1a in 24%, T1b in 45%,T2 in 25% and T3 in 6%. One-hundred and five patients received 55Gy in 5 fractions, 23 received 60Gy in 8, 8 received 54Gy in 3. Overall the treatment was well tolerated: Grade (G)2 and G3 cough in 12 and 2 patients respectively; G2, G3 and G4 dyspnoea in 23, 8 and 1 patients respectively; G2 and G3 fatigue in 26 and 5 patients respectively; G2 chest pain in 10 patients; G2 dysphagia in 2 patients; G2 and G3 anorexia in 4 and 1 patients respectively. Fifteen patients developed progressive disease: 8 with local recurrence, and 7 with distant metastasis. Overall survival at 1, 2 and 3years were 86%, 63% and 54% respectively. The progression free survival at 1, 2 and 3 years were 91%, 79% and 76% respectively. Currently 5-year survival data are pending.


SBRT was effective in this cohort of patients and had low toxicity profile despite pre-existing co-morbidities. Our results compare well for overall survival, local control and toxicity with the published literature.


All authors have declared no conflicts of interest.